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UK SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (UK-SCAP)-A PROSPECTIVE, OBSERVATIONAL STUDY OF THE TREATMENT AND OUTCOMES OF DRUG THERAPY FOR
OBJECTIVES:
The Schizophrenia Care and Assessment Program (SCAP) is a prospective observational study established in the US and Australia to comprehensively measure characteristics of care for schizophrenia patients in actual clinical practice while comparing a wide range of clinical, humanistic, and economic outcomes among older and newer medications. A feasibility study was conducted to investigate the potential for adapting SCAP to Western European countries and to determine appropriate study design. METHODS: The feasibility study was carried out in several countries in Europe and included (1) interviews with providers and planners of healthcare in national associations of psychiatrists, medical associations and national and regional government (2) literature searches on a range of aspects and outcomes of schizophrenia and (3) interviews to assess the key operational aspects of conducting a SCAP study in representative clinical sites. RESULTS: The feasibility study indicated that a UK-SCAP would capture the treatment and budgetary issues raised by UK prescribers and administrators. The wide range of outcomes assessments in SCAP (including sociodemographics, clinical status and treatments, functional status, general health status, quality of life, resource utilisation and carer burden) will distinguish the study and complement data from clinical trials. UK-SCAP will enroll approximately 600 inpatients and outpatients (limited exclusion criteria) from late-1999 and will follow this cohort for 3 years. The primary outcomes measurement tools will be the SCAP instrument, developed from items derived from established measures and validated in the US SCAP study. CONCLUSION: It is important to complement information from randomized clinical trials with information from "real life" settings. As new drug therapies have shown promise for improved treatment of schizophrenia, more research is needed to understand the clinical, humanistic, and economic opportunities of these therapies. Submitted to ECNP Conference, London, September 1999. Series of N-of-1 trials have long been used to help decide the usefulness of interventions in psychology, often where conventional trial designs are impractical or unethical. Recently, N-of-1 trials have been adopted to make decisions on the usefulness of a proven therapy in individual patients. Their use is increasing because many people do not respond to a proven treatment, a greater desire to individualize therapy to enhance the risk/benefit ratio, and cost-containment pressures. N-of-1 trials reduce between-subject variability. They are useful in chronic diseases, where the effects of the active treatment are unlikely to carry-over to the next treatment period. N-of-1 trials provide a unique vehicle for the collection of economic data. Unlike most crossover trials, N-of-1 trials typically involve repeated episodes of the alternative treatments being administered over consecutive cycles. This means that each patient in a series of N-of-1 trials provides multiple observations for each treatment considered. As the required sample size for the economic components of clinical trials have been shown to be large, such trials offer an alternative to large samples that may be unfeasible. In addition, N-of-1 trials provide the means to estimate individual cost-effectiveness ratios, which may be incorporated into the patient, or clinician, decision making process. The problem of follow-up must be addressed, particularly as evaluations measuring QALYs necessarily require a life time horizon. However, if an intermediate outcome can be identified, enabling extrapolation, then this problem can be addressed. Specific examples of the use of this design will be illustrated from the field of dementia, where the 'number needed to treat' to obtain benefit in one patient is high from symptomatic improvement by approved cholinergic agents. The role of economic data from N-of-1 trials to help drug development will also be discussed. 
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ECONOMIC AND OUTCOMES ISSUES OF CARDIOVASCULAR DISEASE
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DIRECT COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS: A MODELING APPROACH
OBJECTIVES:
To estimate the direct costs of maintaining normal sinus rhythm (NSR) in patients with atrial fibrillation (AF) with four antiarrhythmic (AA) drugs (sotalol, amiodarone, flecainide, and propafenone) in the Netherlands (NL). METHODS: A Markov model, with a one month cycle length and a one year treatment duration, was used to estimate expected costs of maintaining NSR. An expert panel of cardiologists was interviewed to collect data on the perceived safety and efficacy of the drugs, resource use (inpatient and outpatient visits, tests and procedures) for recurrence of AF, treatment initiation, monitoring, and side effects. Cost data were obtained principally from the Central Organization for Tariffs in Health Care and the National Association of Pharmacists. Costs were estimated separately by drugs and for patients with and without concomitant structural heart disease (SHD), then weighted by the joint distribution of presence or absence of SHD, specific use of a drug in these two populations, and/or market share of AA drugs.
RESULTS:
The weighted average annual cost of maintaining NSR in an AF patient was US$2,181.31. Inpatient treatment costs, dominated mainly by costs of symptom recurrence and therapy initiation, ranged from 78% (flecainide) to 92% (sotalol) of total costs. Costs of monitoring and side effects were the highest for amiodarone and sotalol, respectively. Drug costs, ranging from $60 for sotalol to $252 for flecainide, were the minor contributors to the total costs. In patients with SHD, annual costs of maintaining NSR were $2,685 and $2,505 for sotalol and amiodarone, the two most common drugs in the NL, respectively. CONCLUSIONS: The estimated annual cost of maintaining NSR in patients with AF in the NL is as high as US$2,685 per patient. Relatively lower AA drug costs are offset by significant medical treatment costs, particularly for inpatient therapy initiation and recurrence of disease symptoms.
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THE COST-EFFECTIVENESS OF CHOLESTEROL-LOWERING TREATMENT IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE: THE CASE OF A COMPREHENSIVE DIETARY INTERVENTION PROGRAM
Long K Section of Health Services Evaluation, Mayo Clinic, Rochester, MN, USA
OBJECTIVES:
No studies to date have addressed the costeffectiveness of lifelong dietary treatment when administered in "real world" community practice. This study examines whether a comprehensive intervention program to detect and treat, through dietary therapy, hypercholesterolemic patients is a cost-effective approach in the primary prevention of morbidity and mortality from coronary heart disease (CHD). METHODS: I developed a multidimensional model of CHD incidence using results from the Physician-Assisted Cholesterol Education Program (PACE), a prospective randomized trial in rural clinical practice, in combination with multivariate logistic risk functions from the Framingham Heart Study. The cost and health effects of this dietary intervention are projected over a lifetime for patients with known CHD risk factors. Results were also simulated for the pharmacologic treatment of lovastatin taken daily in addition to dietary intervention. Changes in life expectancy, quality-adjusted life expectancy, and incremental cost-effectiveness ratios ($/QALY), were the primary outcome measures of interest. RESULTS: PACE participants, on average, reduced their total serum cholesterol levels 1.3% (CI 0.43-2.14). Relative to no treatment, men on dietary treatment gained an estimated 4 to 26 days of quality-adjusted life expectancy at an estimated cost-effectiveness of $14,463 to $77,574 ($/QALY), depending on the age of treatment initiation. Women gained an estimated 3 to 19 days with cost-effectiveness ratios from $49,998 to $102,574 ($/QALY). Relative to dietary treatment alone, the cost-effectiveness of the combined diet-plus-lovastatin treatment ranged from $43,620 to $49,776 ($/QALY) in men, and from $52,996 to $74,718 ($/QALY) in women. CONCLUSIONS: Dietary intervention is a relatively costeffective method of CHD prevention and should remain the preferred treatment option for younger men and women-especially for those initially at highest risk of CHD. Combined diet-plus-lovastatin therapy, however, is the optimal treatment choice for older individuals and for those who experience a reduced quality of life on stringent dietary regimes. 
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COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER IN THE UNITED STATES
OBJECTIVES:
The objective of the study was to estimate the direct costs of maintaining normal sinus rhythm (NSR) in patients with atrial fibrillation or flutter (AF/F) with five antiarrhythmic (AA) agents (amiodarone, flecainide, propafenone, quinidine, sotalol). METHODS: A Markov model was used to estimate the expected costs of maintaining NSR in patients with AF/F using AA therapies. Estimates of the resource utilization (inpatient therapy initiation and monitoring, recurrence,
